SOHO 2023 | Factors influencing treatment selection for patients with relapsed multiple myeloma
Marc Braunstein, MD, PhD, NYU Long Island School of Medicine, New York City, NY, provides an overview of the factors that should be considered during treatment selection for patients with relapsed multiple myeloma (MM). Dr Braunstein comments on the importance of accounting for patient-related variables, such as response to prior therapies, prior toxicities, and whether the patient has received a stem cell transplant (SCT). It is also necessary to consider disease-related variables and identify any high-risk features, including mutations that confer sensitivity to specific therapies. Dr Braunstein concludes by discussing treatment-related variables which influence treatment selection, including the accessibility of centers delivering novel therapies such as bispecific antibodies and CAR-T cells. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
AbbVie: Consultant (advisory board), Adaptive Biotechnologies: Consultant (advisory board)
ADC Therapeutics: Consultant (advisory board), American College of Physicians: MSKAP Question Writer, Bristol Myers Squibb: Consultant (advisory board), Janssen: Faculty bureau, Bristol Myers Squibb: Research funding, CTI Biopharma: Consultant (advisory board), Epizyme: Consultant (advisory board), Glaxosmithkline: Consultant (advisory board), Guidepoint: Consultant, Janssen: Consultant (advisory board), Janssen: Research funding, LAVA Therapeutics: Consultant (advisory board), Pfizer: Consultant (advisory board), Pfizer/ICON: Clinical independent reviewer, Sanofi: Consultant, Seagen: Consultant (advisory board)
